uniQure - QURE Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.

7 brokers have issued 1 year price targets for uniQure's shares. Their QURE share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $48.71 in the next twelve months. This suggests a possible upside of 87.1% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.

uniQure's stock was trading at $20.74 on January 1st, 2022. Since then, QURE stock has increased by 25.5% and is now trading at $26.03.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our QURE earnings forecast.

uniQure (NASDAQ:QURE) issued its quarterly earnings data on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.26. The biotechnology company had revenue of $2 million for the quarter, compared to analyst estimates of $2.13 million. uniQure had a negative net margin of 204.12% and a negative trailing twelve-month return on equity of 24.47%. The company's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.21) EPS.

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.46%), Point72 Asset Management L.P. (9.10%), State Street Corp (6.54%), PFM Health Sciences LP (5.11%), Vanguard Group Inc. (3.06%) and 683 Capital Management LLC (2.93%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends.

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $26.03.

uniQure (NASDAQ:QURE) has a market capitalization of $1.22 billion and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.69) on an earnings per share basis.

The company employs 463 workers across the globe.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.